Join the 'Chronic Obstructive Pulmonary Disease' group to help and get support from people like you.

Chronic Obstructive Pulmonary Disease Blog

Related terms: Bronchitis, Chronic, Bronchitis with Airway Obstruction, Chronic Bronchitis, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease, Emphysema, COPD

FDA Approves Striverdi Respimat - New Treatment for People With COPD

Posted 9 hours ago by Drugs.com

FRIDAY, Aug. 1, 2014 – Patients with the progressive, deadly respiratory ailment known as chronic obstructive pulmonary disease (COPD) have a new weapon to battle the disease, the U.S. Food and Drug Administration said Thursday. The agency approved a new treatment, an inhaled spray called Striverdi Respimat (olodaterol) for COPD, the third leading killer of Americans. COPD, which is often linked to smoking, involves multiple lung conditions such as chronic bronchitis and emphysema. Patients with COPD may experience a number of symptoms, such as wheezing, coughing and tightness in their chest. According to the FDA, Striverdi Respimat belongs to a class of medicines known as long-acting beta-adrenergic agonists (LABAs). The agency said the drug works by helping the airway muscles in the lungs stay relaxed, and it can be taken once daily over a prolonged period of time. "The availability ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance

Once-Daily Striverdi Respimat Inhaler Approved for COPD

Posted 1 day 4 hours ago by Drugs.com

THURSDAY, July 31, 2014 – Striverdi Respimat (olodaterol) inhalation spray has been approved by the U.S. Food and Drug Administration to treat chronic obstructive pulmonary disease (COPD), the agency said Thursday in a news release. COPD, which includes chronic bronchitis and chronic emphysema, is a progressive disease that makes breathing difficult by obstructing airflow through the lungs. Most commonly caused by smoking, it's the third-leading cause of death in the United States, the FDA said. The once-daily inhaler relaxes lung airways, improving breathing. It was evaluated in a clinical study of more than 3,100 people diagnosed with COPD. The drug's label will carry a boxed warning that it increases the risk of asthma-related death. The FDA said Striverdi Respimat hasn't been evaluated among people with asthma and is not approved to treat asthma or sudden breathing problems such as ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance

FDA Approves Striverdi Respimat to Treat Chronic Obstructive Pulmonary Disease

Posted 1 day 4 hours ago by Drugs.com

July 31, 2014 – Today, the U.S. Food and Drug Administration approved Striverdi Respimat (olodaterol) inhalation spray to treat patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema that are experiencing airflow obstruction. Striverdi Respimat can be used once daily over a long period of time. COPD is a serious lung disease that makes breathing difficult and worsens over time. Symptoms can include wheezing, cough, chest tightness, and shortness of breath. Cigarette smoking is the leading cause of COPD. According to the National Heart, Lung, and Blood Institute, COPD is the third leading cause of death in the United States. “The availability of this new long-term maintenance medication provides an additional treatment options for the millions of Americans who suffer with COPD,” said Curtis Rosebraugh, M.D., M.P.H., director of the Off ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance

Annual COPD Costs To Hit $49 Billion by 2020: CDC

Posted 2 days 6 hours ago by Drugs.com

WEDNESDAY, July 30, 2014 – Medical costs for chronic obstructive pulmonary disease (COPD) in the United States are more than $32 billion each year, according to new research from the U.S. Centers for Disease Control and Prevention. The yearly financial toll of COPD (which includes emphysema and chronic bronchitis) is expected to reach an estimated $49 billion by 2020. "For the first time, our analyses provide state-specific costs for COPD, which provide state public health practitioners with estimates of the economic burden of COPD within their borders and illustrates the potential medical and absenteeism costs savings to states through implementing state level programs that are designed to prevent the onset of COPD," Dr. Earl Ford, of the CDC's division of population health, said in a news release from the journal CHEST. Medical costs associated with COPD were primarily paid for by ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute

Obesity May Raise Risk of COPD

Posted 7 Jul 2014 by Drugs.com

MONDAY, July 7, 2014 – Obese people, particularly those with excess belly fat, may face a higher risk of developing chronic obstructive pulmonary disease (COPD), a new study suggests. The researchers report that women with a waist size of roughly 43 inches or more and men with waist size of 46 inches or more showed a 72 percent increased risk of developing the lung disease, compared with people who had a normal waist size. COPD, also known as emphysema and chronic bronchitis, is the third leading cause of death in the United States, according to the American Lung Association. "It is already known that COPD may be prevented by avoiding exposure to tobacco smoke, air pollution and occupational dust damaging the lungs," said lead researcher Gundula Behrens, from the department of epidemiology and preventive medicine at the University of Regensburg in Germany. "But maintaining a normal ... Read more

Related support groups: Obesity, Chronic Obstructive Pulmonary Disease

COPD Patients Face Greater Risk of Heart Failure, Study Says

Posted 25 May 2014 by Drugs.com

WEDNESDAY, May 21, 2014 – People with the lung condition known as chronic obstructive pulmonary disease (COPD) have a significantly increased risk of developing heart failure, and the risk is highest among black patients, according to a new study. Researchers analyzed more than 386 million hospital patient discharge records in the United States from 2001 through 2010, including more than 33 million COPD patients aged 40 and older. Nearly 29 percent of COPD patients had heart failure, compared with 13 percent of patients without COPD. The researchers then analyzed the data by race and found that about 35 percent of blacks with COPD had heart failure, compared with about 15 percent of blacks without COPD. Among whites, nearly 29 percent of those with COPD and nearly 13 percent of those without COPD had heart failure. Among people of other races, the rates were about 25 percent and 11 ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

Diet Tied to Better Breathing in COPD Patients

Posted 21 May 2014 by Drugs.com

WEDNESDAY, May 21, 2014 – People with certain chronic lung diseases might breathe a bit easier when their diets contain healthy foods like fruits and fish, a new study suggests. Researchers found that among nearly 2,200 adults with chronic obstructive pulmonary disease (COPD), those who ate fish, grapefruit, bananas and cheese tended to have better lung function and fewer symptoms than their counterparts who did not eat those foods. COPD is an umbrella term for the progressive lung diseases emphysema and chronic bronchitis. In the United States, about 15 million people have COPD, and the disease is the third leading cause of death nationwide, according to the U.S. Centers for Disease Control and Prevention. Smoking is the leading cause of COPD. It's not clear yet whether diet has direct effects on COPD patients' lungs. The new study, reported at the American Thoracic Society's annual ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

Heat Waves Could Worsen COPD Symptoms, Study Suggests

Posted 18 May 2014 by Drugs.com

SUNDAY, May 18, 2014 – As air temperatures rise, so too may the symptoms of the chronic respiratory illness COPD, a new study suggests. The problem might be even more dire if predictions about global warming come to pass, the study's authors said. The study was slated for presentation Sunday in San Diego at the annual meeting of the American Thoracic Society. Getting a better understanding of who is most vulnerable to rising temperatures "is increasingly important in order to anticipate and prepare for health effects related to climate change," the study's lead author, Dr. Meredith McCormack, of Johns Hopkins University in Baltimore, said in a meeting news release. "These findings support the need for adaptive approaches to COPD treatment to prevent adverse health effects related to increases in temperature," she said. Chronic obstructive pulmonary disorder, or COPD, refers to a group ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

FDA Approves Incruse Ellipta (umeclidinium) for the Treatment of COPD

Posted 6 May 2014 by Drugs.com

London UK - 30 April 2014, GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Incruse Ellipta (umeclidinium) as an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium is GSK’s first once-daily anticholinergic, a type of bronchodilator also known as a long-acting muscarinic antagonist (LAMA), and is contained in the Ellipta® inhaler. The FDA-approved strength is 62.5 mcg. Following this approval by the FDA, it is anticipated that launch activities in the US will commence during the fourth quarter of 2014. The phase III pivotal programme for umeclidinium included seven clinical studies which involved over 2,500 COPD patients treated with umeclidinium or placebo. About CO ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance

Smoke-Free Laws May Help Prevent COPD Hospitalizations

Posted 25 Apr 2014 by Drugs.com

FRIDAY, April 25, 2014 – People who have chronic obstructive pulmonary disease, or COPD, are less likely to be hospitalized for breathing problems if they live in an area where local laws prohibit smoking in public spaces including bars, restaurants and offices, a new study shows. "Kentuckians with COPD that live in a community with strong smoke-free laws were 22 percent less likely to be put in the hospital compared to those who were in a community with no law or a weak law," said study author Ellen Hahn, director of the Tobacco Policy Research Program at the University of Kentucky's College of Nursing in Lexington. COPD is a progressive lung disease characterized by chronic inflammation of the airways. People who have COPD often feel short of breath, or they may cough or wheeze. Medication can help control the symptoms, but there's no cure. It's currently the third leading cause of ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Smoking Cessation

Certain Sedatives Tied to Breathing Problems in Older COPD Patients

Posted 18 Apr 2014 by Drugs.com

FRIDAY, April 18, 2014 – A group of widely used sedatives increases the risk of serious breathing problems in older people with the lung condition called chronic obstructive pulmonary disease (COPD), a new study says. Benzodiazepines such as lorazepam (Ativan) or alprazolam (Xanax) are commonly prescribed to treat insomnia and anxiety, the study author noted. For the study, researcher Dr. Nicholas Vozoris examined the medical records of older adults with COPD in the Canadian province of Ontario. Those who had been newly prescribed a benzodiazepine had a 45 percent increased risk of experiencing breathing problems that required outpatient treatment. These patients also had a 92 percent greater risk of needing to go to the emergency room for treatment of pneumonia or COPD, and were more likely to be hospitalized for breathing problems, according to the study published online April 17 in ... Read more

Related support groups: Xanax, Klonopin, Clonazepam, Valium, Ativan, Chronic Obstructive Pulmonary Disease, Alprazolam, Lorazepam, Diazepam, Temazepam, Restoril, Xanax XR, Librium, Oxazepam, Halcion, Serax, Midazolam, Triazolam, Versed, Chlordiazepoxide

Exercise May Curtail COPD Complications

Posted 9 Apr 2014 by Drugs.com

WEDNESDAY, April 9, 2014 – Exercise might help reduce the risk of hospital readmission in people with a progressive lung condition called chronic obstructive pulmonary disease (COPD), a new study finds. "Our findings suggest that regular physical activity could buffer the stresses of hospitalization," said study author Huong Nguyen, of the Kaiser Permanente Southern California Department of Research and Evaluation. "Future studies will focus on determining whether we can reduce hospitalizations by improving physical activity in patients with COPD," Nguyen added. COPD refers to a group of diseases, including emphysema and chronic bronchitis, that cause airflow blockage and breathing problems. Fifteen million Americans report they have a COPD diagnosis, according to the U.S. Centers for Disease Control and Prevention. For this study, published April 9 in the Annals of the American ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

COPD May Damage Aging Brain

Posted 18 Mar 2014 by Drugs.com

TUESDAY, March 18, 2014 – Seniors with chronic obstructive pulmonary disease (COPD) have an increased risk of developing mental decline, especially thinking problems without apparent memory loss, a new study suggests. This diminished brain function – called "nonamnestic" mild cognitive impairment – was significantly more common among older adults with COPD than those without the disabling respiratory disorder, according to the study of more than 1,400 adults. "We found that COPD was associated with problems with attention, planning and problem-solving, but not with memory," said study co-author Michelle Mielke, an associate professor with the division of epidemiology at the Mayo Clinic in Rochester, Minn. "This is important, because for one thing COPD is potentially preventable," Mielke said. Also, in order to preserve long-term mental functioning, this finding highlights the need to ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

2-Mile Daily Walk Might Help Fight COPD

Posted 5 Mar 2014 by Drugs.com

WEDNESDAY, March 5, 2014 – Taking daily walks of at least two miles can reduce hospitalizations from severe episodes of a life-threatening breathing disorder, new research suggests. Scientists found that chronic obstructive pulmonary disease (COPD) patients without regular walking regimens had about twice the rate of hospitalizations triggered by the condition compared to those who maintained the highest levels of physical activity. This was defined as walking between roughly two and four miles each day. "Of course, daily walking acts to improve the exercise capacity of these patients," said study author Dr. Cristobal Esteban, a staff member in the respiratory service at Hospital Galdakao-Usansolo, in Spain. "Physical activity is a 'medicine' that will improve your general condition as well as COPD." The study appeared online recently in the journal Respirology. The third-leading cause ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

FDA Approves Anoro Ellipta to Treat COPD

Posted 18 Dec 2013 by Drugs.com

WEDNESDAY, Dec. 18, 2013 – A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration. GlaxoSmithKline's Anoro Ellipta is meant to be used once a day for long-term maintenance of airflow in patients with COPD. The lung disease makes breathing difficult and worsens over time. "Anoro Ellipta works by helping the muscles around the airways of the lungs stay relaxed to increase airflow in patients with COPD," Dr. Curtis Rosebraugh, director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research, said in an agency news release. "The availability of new long-term maintenance medications provides additional treatment options for the millions of Americans who suffer with COPD," he added. Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease

Page 1 2 3 4 5 6 7 Next

Ask a Question

Further Information

Related Condition Support Groups

Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute, Alpha-1 Proteinase Inhibitor Deficiency, Respiratory Tract Disease

Related Drug Support Groups

prednisone, Symbicort, montelukast, Daliresp, Bronchial, Breo Ellipta, Bronkometer, Tudorza Pressair, Rayos, view more... isoetharine, guaifenesin/theophylline, Broncomar GG, Theolate, Uni Bronchial, Theocon, Theophyll-GG, Bronkosol, Broncodur, Glyceryl T, Ed-Bron G, Equibron G, Theo G, Solu-Phyllin GG, Lufyllin-400, umeclidinium/vilanterol, umeclidinium, Dylix, fluticasone/vilanterol, aclidinium, dyphylline, roflumilast, Dilor, Lufyllin, Dilor-400, Asbron G, budesonide/formoterol, Neothylline, Quibron, Theomar GG, Slo-Phyllin GG